Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F25%3A00085903" target="_blank" >RIV/00023001:_____/25:00085903 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S1600613525002953?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1600613525002953?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ajt.2025.06.003" target="_blank" >10.1016/j.ajt.2025.06.003</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction

Popis výsledku v původním jazyce

Targeting peritransplant inflammation via tumor necrosis factor alpha blockade failed to improve kidney transplantation outcomes in the CTOT-19 trial that tested infliximab (IFX) induction. As natural antibodies (nAbs) to cardiolipin and phosphatidylethanolamine promote graft injury, we hypothesized that CTOT-19 outcomes were confounded by nAb levels. Pretransplant plasma anticardiolipin (aCL) and antiphosphatidylethanolamine (aPE) immunoglobulin M/immunoglobulin G (IgM/IgG) were measured in 177 CTOT-19 subjects and analyzed in relation to delayed graft function (DGF), 2-year estimated glomerular filtration rate, and infection. Bayesian modeling with a nonlinear treatment-antibody interaction estimated that the IFX effects depend on aCL IgG/IgM and aPE IgG. In patients with low aCL IgG, IFX reduces DGF risk (odds ration [OR] at the fifth percentile, 0.13; 95% credible interval (95% CrI), 0.03-0.49) but increases risk at the 95th percentile of aCL IgG levels (OR, 6.24; 95% CrI, 1.38-30.32). In patients with aCL IgG below the median, IFX has a positive indirect effect on the estimated glomerular filtration rate via reducing DGF rates. Finally, IFX increases infection risk in patients with low aPE IgG (OR at the fifth percentile, 3.12; 95% CrI, 1.11-9.08). This analysis identifies a subset of CTOT-19 subjects who likely benefit from IFX and suggests pretransplant nAb levels may serve as biomarkers for response to early posttransplant anti-inflammatory therapies.

Název v anglickém jazyce

Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction

Popis výsledku anglicky

Targeting peritransplant inflammation via tumor necrosis factor alpha blockade failed to improve kidney transplantation outcomes in the CTOT-19 trial that tested infliximab (IFX) induction. As natural antibodies (nAbs) to cardiolipin and phosphatidylethanolamine promote graft injury, we hypothesized that CTOT-19 outcomes were confounded by nAb levels. Pretransplant plasma anticardiolipin (aCL) and antiphosphatidylethanolamine (aPE) immunoglobulin M/immunoglobulin G (IgM/IgG) were measured in 177 CTOT-19 subjects and analyzed in relation to delayed graft function (DGF), 2-year estimated glomerular filtration rate, and infection. Bayesian modeling with a nonlinear treatment-antibody interaction estimated that the IFX effects depend on aCL IgG/IgM and aPE IgG. In patients with low aCL IgG, IFX reduces DGF risk (odds ration [OR] at the fifth percentile, 0.13; 95% credible interval (95% CrI), 0.03-0.49) but increases risk at the 95th percentile of aCL IgG levels (OR, 6.24; 95% CrI, 1.38-30.32). In patients with aCL IgG below the median, IFX has a positive indirect effect on the estimated glomerular filtration rate via reducing DGF rates. Finally, IFX increases infection risk in patients with low aPE IgG (OR at the fifth percentile, 3.12; 95% CrI, 1.11-9.08). This analysis identifies a subset of CTOT-19 subjects who likely benefit from IFX and suggests pretransplant nAb levels may serve as biomarkers for response to early posttransplant anti-inflammatory therapies.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30213 - Transplantation

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

American journal of transplantation

ISSN

1600-6135

e-ISSN

1600-6143

Svazek periodika

25

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

2173-2181

Kód UT WoS článku

001589464400014

EID výsledku v databázi Scopus

2-s2.0-105009075531